Investors - Imexpharm

Financial information

IMP - Reviewed Interim Financial statements for 2026

IMP - 2Q and 6M 2026 Business Results

IMP - Press release: Second Quarter and First Half 2026 Results

IMP - Financial Statements Q2/2026

IMP - 5M2026 Business Updates

IMP - 1Q and 4M 2026 Business Results

IMP – Explanation of change in Profit after tax in Q1/2026

IMP - Financial Statements Q1/2026

IMP - Press release: Imexpharm Corporation announces first quarter 2026 business results

IMP - 2Q and 6M 2026 Business Results

IMP - Press release: Second Quarter and First Half 2026 Results

IMP - 5M2026 Business Updates

IMP - 1Q and 4M 2026 Business Results

IMP - Press release: Imexpharm Corporation announces first quarter 2026 business results

IMP - 2M2026 Business Updates

IMP - 4Q2025 and FY2025 business results

IMP - Press release: Imexpharm Corporation announces 4Q2025 and FY2025 business results

IMP - 11M2025 Business Updates

IMP - Reviewed Interim Financial statements for 2026

IMP - Financial Statements Q2/2026

IMP – Explanation of change in Profit after tax in Q1/2026

IMP - Financial Statements Q1/2026

IMP - Audited Financial Statements for the year end 31 Dec 2025

IMP – Explanation of change in Profit after tax in Q4.2025

IMP - Financial Statements Q4/2025

IMP - Financial Statements Q3/2025

IMP - Disclosure of reviewed 6 month 2025 Financial statements and explanation for PAT growth

Annual Report & Sustainability Report

Sustainability Report 2025

Sustainability Report 2025

Annual Report 2025

Annual Report 2025

Annual Report 2024 (Digital version)

Annual Report 2024 (Digital version)

Sustainability Report 2024

Sustainability Report 2024

Annual Report 2024 (PDF version)

Annual Report 2024 (PDF version)

Sustainability Report 2023

Sustainability Report 2023

Annual Report 2023 (Digital version)

Annual Report 2023 (Digital version)

Annual Report 2023 (PDF version)

Annual Report 2023 (PDF version)

Sustainability Report 2022

Sustainability Report 2022

Annual Report 2025

Annual Report 2025

Annual Report 2024 (Digital version)

Annual Report 2024 (Digital version)

Annual Report 2024 (PDF version)

Annual Report 2024 (PDF version)

Annual Report 2023 (Digital version)

Annual Report 2023 (Digital version)

Annual Report 2023 (PDF version)

Annual Report 2023 (PDF version)

Annual Report 2022

Annual Report 2022

Annual Report 2021

Annual Report 2021

Annual Report 2020

Annual Report 2020

Annual Report 2019

Annual Report 2019

Sustainability Report 2025

Sustainability Report 2025

Sustainability Report 2024

Sustainability Report 2024

Sustainability Report 2023

Sustainability Report 2023

Sustainability Report 2022

Sustainability Report 2022

Sustainability Report 2021

Sustainability Report 2021

Sustainability Report 2020

Sustainability Report 2020

Sustainability Report 2019

Sustainability Report 2019

Sustainability Report 2018

Sustainability Report 2018

AGM

IMP - The Minutes of Vote counting result and the Resolution of the GMS approving certain matters via written consultation in 2026

06/23/2026

IMP - Notice on Collecting Shareholders' Opinions via Written Ballots in 2026

06/12/2026

IMP - Resolution of the 2026 AGM

04/23/2026

IMP - Meeting minutes of the 2026 AGM

04/23/2026

IMP - Documents for the 2026 Annual General Meeting of Shareholders

03/25/2026

IMP - Notice of the convening of the 2026 AGM

03/25/2026

IMP - The Minutes of Vote counting result and the Resolution of the GMS approving certain matters via written consultation

10/29/2025

IMP - Notice on Collecting Shareholders' Opinions via Written Ballots in 2025

10/14/2025

IMP - Notice on Collecting Shareholders' Opinions via Written Ballots in 2026

06/12/2026

IMP - Documents for the 2026 Annual General Meeting of Shareholders

03/25/2026

IMP - Notice of the convening of the 2026 AGM

03/25/2026

IMP - Notice on Collecting Shareholders' Opinions via Written Ballots in 2025

10/14/2025

IMP - Documents for the 2025 Annual General Meeting of Shareholders

04/03/2025

IMP - Announcement attend the AGM 2025

03/28/2025

IMP - Documents to collect GMS's opinions in writing (2nd time in 2024)

10/17/2024

IMP - Documents to collect GMS's opinions in writing

07/25/2024

IMP - The Minutes of Vote counting result and the Resolution of the GMS approving certain matters via written consultation in 2026

06/23/2026

IMP - Resolution of the 2026 AGM

04/23/2026

IMP - Meeting minutes of the 2026 AGM

04/23/2026

IMP - The Minutes of Vote counting result and the Resolution of the GMS approving certain matters via written consultation

10/29/2025

IMP - Official letter amending the Resolution and Minutes of the 2025 AGM

05/15/2025

IMP - Meeting minutes of the 2025 AGM

04/26/2025

IMP - Resolution of the 2025 AGM

04/26/2025

IMP - Resolution of the GMS No. 04 approving the implementation of the Cat Khanh Pharmaceutical Factory Complex Project

10/30/2024

Corporate Governance

IMP - Report on Corporate Governance for 1H2026

07/30/2026

IMP - Imexpharm Corporation’s amended and supplemented Charter was approved by the GMS on April 22, 2026

04/23/2026

IMP - Report on Corporate Governance for 2025

01/30/2026

IMP - The BOD’s Resolution on the issuance of the Information Disclosure Regulations (2nd amendment)

01/08/2026

IMP - Report on Corporate Governance for 1H2025

07/25/2025

IMP - Imexpharm's Charter - April 2025 (amended on May 15, 2025)

05/15/2025

IMP - Internal regulations on Corporate Governance - April 2025

04/26/2025

IMP - Imexpharm's Charter - April 2025

04/26/2025

IMP - Imexpharm Corporation’s amended and supplemented Charter was approved by the GMS on April 22, 2026

04/23/2026

IMP - The BOD’s Resolution on the issuance of the Information Disclosure Regulations (2nd amendment)

01/08/2026

IMP - Imexpharm's Charter - April 2025 (amended on May 15, 2025)

05/15/2025

IMP - Internal regulations on Corporate Governance - April 2025

04/26/2025

IMP - Imexpharm's Charter - April 2025

04/26/2025

IMP - Nomination and Compensation Committee Regulation

02/24/2025

IMP - Regulation on operation of Audit Committee

02/24/2025

IMP - Imexpharm's Charter - October 2024

10/01/2024

IMP - Report on Corporate Governance for 1H2026

07/30/2026

IMP - Report on Corporate Governance for 2025

01/30/2026

IMP - Report on Corporate Governance for 1H2025

07/25/2025

IMP - Report on Corporate Governance for 2024

01/23/2025

IMP - Report on Corporate Governance for 1H2024

07/30/2024

IMP: Report on Corporate Governance in 2023

01/30/2024

IMP: Report on Corporate Governance for the first 6 months of 2023

07/28/2023

IMP – Report on Corporate Governance in 2022

01/30/2023

Imexpharm – Prospectus for Public Offering of Shares 2010

11/16/2010

Information Disclosure

IMP - Reviewed Interim Financial statements for 2026

08/14/2026

IMP - Report on Corporate Governance for 1H2026

07/30/2026

IMP - Financial Statements Q2/2026

07/20/2026

IMP - HOSE Announcement on the Record Date for 2025 Cash Dividend Payment

07/06/2026

IMP - Notice on record date for exercising the right to the 2025 cash dividend payment)

06/30/2026

IMP - BOD Resolution on the 2025 Cash Dividend Payment to Shareholders

06/30/2026

IMP - Change in personnel

06/30/2026

IMP - Board of Directors' Decisions on the Election of the Chairperson of the BOD and the Appointment of Other Personnel

06/30/2026

Analyst Report

Analyst Report

HSC - Initial Valuation Report

SSI - Valuation update report

FPTS - Valuation update report

PHS - Flash Note: Leading position, Sustainable growth

PHS - Company meeting note

SSI - Positive Outlook for 2H and Beyond

VDSC - Business update 1Q2024

Vietcap - Visit note

FPTS - Valuation update report

News - Events

2Q2026 - Imexpharm Facts & Figures

07/23/2026

2Q2026 - Imexpharm Facts & Figures

Imexpharm 1H2026 Earnings Call Invitation

07/14/2026

Imexpharm 1H2026 Earnings Call Invitation

IMP - Imexpharm Corporation announces its plan to restructure the Board of Directors

IMP - Imexpharm Corporation announces its plan to restructure the Board of Directors

05/22/2026

Imexpharm organizes scientific seminar introducing treatment solutions for musculoskeletal disorders

Imexpharm organizes scientific seminar introducing treatment solutions for musculoskeletal disorders

05/14/2026

Imexpharm 1Q2026 Earnings Call Invitation

Imexpharm 1Q2026 Earnings Call Invitation

05/11/2026

IMP - Press Release: 2026 Annual General Meeting of Shareholder

IMP - Press Release: 2026 Annual General Meeting of Shareholder

04/22/2026

Top 50 best listed companies

Top 50 best listed companies

In 2024, Imexpharm was voted Top 50 best listed companies of the year by Forbes Vietnam Magazine. Being named on the list for the third time, Imexpharm shows its solid preparation of internal strength, ready for the next steps on its 47-year development journey.